FDA approved Novartis Scembli for chronic myeloid leukemia

ESMO 2020

Novartis Beovu demonstrated non-inferiority vs. aflibercept in the PEP and superiority in SEP

MSVirtual2020: Novartis and Roche, two Swiss giants, presents robust trial results of their assets